Preferred Label : Sasanlimab;
NCIt synonyms : Anti-PD-1 PF-06801591; WHO 11161;
NCIt definition : An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1),
with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,
sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its
ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation
of PD-1 and its downstream signaling pathways. This may restore immune function through
the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against
tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is
expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune
checkpoint that negatively regulates T-cell activation and effector function when
activated by its ligands, and plays an important role in tumor evasion from host immunity.;
UNII : LZZ0IC2EWP;
CAS number : 2206792-50-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2206792-50-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : PF-06801591;
NCI Metathesaurus CUI : CL502495;
Origin ID : C124058;
UMLS CUI : C5418170;
Semantic type(s)
- concept_is_in_subset
- has_target
